Table 1.
F. tularensis subsp. holarctica mutants: Protection against subsp. tularensis SCHU S4 respiratory challenge.
| Vaccinea | Host strain | Vaccine route, dose (CFU)b | Boost (route) | LVS control (route) | Interval (days)c | SCHU S4 challenge route, dose (CFU) | % Survival post-challenge (MST, days)d | References | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine | LVS | Sham | ||||||||
| NUTRIENT METABOLIC MUTANT | ||||||||||
| LVS ΔpurMCD | BALB/c | i.n., 106 | No | Yes (i.n.) | 42 | i.n., 100 | 0 (6) | 100 (21) | 0 (5) | Pechous et al., 2008 |
| i.n., 2000 | 0 (5) | 0 (7) | 0 (5) | |||||||
| BALB/c | i.n., 106 | Yes (i.n.) | Yes (i.n.) | 21 | i.n., 100 | 100 (21) | 100 (21) | 0 (5) | Pechous et al., 2008 | |
| i.n., 2000 | 33 (17) | 33 (11) | 0 (5) | |||||||
| OXIDATIVE STRESS RESPONSE MUTANTS | ||||||||||
| LVS ΔsodBFt | C57BL/6 | i.n., 5 × 103 | No | Yes (i.n.) | 21 | i.n., 14 | 40 | 0 (12) | 0 (7) | Bakshi et al., 2006, 2008 |
| C57BL/6 | i.n., 5 × 102 | Yes (i.n.) | Yes (i.n.) | 21 | i.n., 103 | 42 | 0 (15) | 0 (6) | Bakshi et al., 2006, 2008 | |
| emrA1 | C57BL/6 | i.n., 106 | No | No | 21 | i.n., 32 | 0 (8) | ND | 0 (6) | Suresh et al., 2015 |
| i.n., 106 | Yes (i.n.) | No | 21 | i.n., 38 | 0 (9) | ND | 0 (6) | Suresh et al., 2015 | ||
| i.d., 106 | Yes (i.d.) | No | 21 | i.n., 17 | 0 (10) | ND | 0 (7) | Suresh et al., 2015 | ||
| i.d., 106 | Yes (i.n.) | No | 21 | i.n., 17 | 0 (10) | ND | 0 (7) | Suresh et al., 2015 | ||
| i.n., 103 | Yes (i.d.) | No | 21 | i.n., 23 | 20 | ND | 0 (6) | Suresh et al., 2015 | ||
| i.d., 103 | Yes (i.n.) | No | 21 | i.n., 24 | 20 | ND | 0 (6) | Suresh et al., 2015 | ||
| ΔdsbA/FSC200 | BALB/c | i.n., 102 | No | No | 28 | i.n., 100 | 0 | ND | 0 (5) | Straskova et al., 2015 |
| i.n. 103 | No | No | 28 | i.n., 100 | 0 | ND | 0 (5) | Straskova et al., 2015 | ||
| i.n., 104 | No | No | 28 | i.n., 100 | 20 | ND | 0 (5) | Straskova et al., 2015 | ||
| i.n., 105 | No | No | 28 | i.n., 100 | 30 | ND | 0 (5) | Straskova et al., 2015 | ||
| i.n., 106 | No | No | 28 | i.n., 100 | 50 | ND | 0 (5) | Straskova et al., 2015 | ||
| HEAT SHOCK PROTEIN MUTANTS | ||||||||||
| LVS ΔclpB | BALB/c | i.d., 105 | No | No | 42 | i.n. 40 | 0 (~12) | ND | 0 (5) | Golovliov et al., 2013 |
| FSC200 ΔclpB | BALB/c | i.d., 105 | No | Yes (i.d.) | 42 | i.n. 86 | 40 | 0 | 0 (5) | Golovliov et al., 2013 |
| CAPSULAR AND MEMBRANE MUTANTS | ||||||||||
| LVS ΔcapB | BALB/c | i.d., 106 | No | Yes (i.d.) | 42 | Aero., 10 | 0 (10) | 67 (16) | 0 (5) | Jia et al., 2010 |
| i.n., 105 | No | Yes (i.n.) | 42 | Aero. 10 | 100 (21) | 100 (21) | 0 (5) | Jia et al., 2010 | ||
| rLVS ΔcapB /IglA |
BALB/c | i.d., 106 | No | Yes (i.d.) | 42 | Aero., 10 | 50 (16) | 63 (17) | 0 (5) | Jia et al., 2013 |
| rLVS ΔcapB /IglC |
BALB/c | i.d., 106 | No | Yes (i.d.) | 42 | Aero., 10 | 40 (14) | 63 (17) | 0 (5) | Jia et al., 2013 |
| rLVS ΔcapB /IglABC |
BALB/c | i.d., 106 | No | Yes (i.d.) | 42 | i.n., 16–31 | 0 | 50 | 0 (4) | Jia et al., 2016 |
| BALB/c | i.d., 106 | Yes (i.d.) | Yes (i.d.) | 42 | i.n., 10 | 50 | 50-75 | 0 (4) | Jia et al., 2018 | |
| BALB/c | i.n., 106 | Yes (i.n.) | Yes (i.d.) | 42 | i.n., 6-10 | 83-100 | 50-75 | 0 (4) | Jia et al., 2018 | |
| LVS::Δwzy | BALB/c | i.n., 3.5 × 106 | Yes (i.n.) | Yes (i.n.) | 28 | i.n., 8 | 84 | 100 | 0 (6) | Kim et al., 2012 |
| LVS::wbtA-OPS-TT* | BALB/c | i.n., 1.5 × 107 | Yes (i.n.) | No | 28 | i.n., 10 | 40 (15) | ND | 20 (7) | Sebastian et al., 2009 |
| LVS::ΔwbtA | BALB/c | i.n., 3.7 × 106 | Yes (i.n.) | Yes (i.n.) | 28 | i.n., 8 | 0 | 100 | 0 (6) | Kim et al., 2012 |
| FTL_0057 | BALB/c | i.n., 107 | No | No | 30 | i.n., 100 | 100 | ND | 0 (6) | Mahawar et al., 2013 |
| FTL_0325 | BALB/c | i.n., 107 | No | No | 30 | i.n., 100 | 100 | ND | 0 (6) | Mahawar et al., 2013 |
| OTHER MUTANTS | ||||||||||
|
LVS FTL0552 (pmrA) |
BALB/c | i.n., 105 | No | No | 30 | i.n., 100 | 30 | ND | 0 (6) | Sammons-Jackson et al., 2008 |
| BALB/c | i.n., 105 | Yes (i.n.) | No | 30 | i.n., 100 | 40 | ND | 0 (6) | Sammons-Jackson et al., 2008 | |
| C57BL/6 | i.n., 104 | No | No | 30 | i.n., 100 | 0 (9) | ND | 0 (7) | Sammons-Jackson et al., 2008 | |
| C57BL/6 | i.n., 104 | Yes (i.n.) | No | 30 | i.n., 100 | 0 (16) | ND | 0 (7) | Sammons-Jackson et al., 2008 | |
| FTL_0291 | BALB/c | i.n., 107 | No | No | 30 | i.n., 100 | 100 | ND | 0 (6) | Mahawar et al., 2013 |
| FTL_0304 | BALB/c | i.n., 107 | No | No | 30 | i.n., 100 | 0 (12) | ND | 0 (6) | Mahawar et al., 2013 |
a
Vaccine:
*
, animals vaccinated simultaneously with LVS::wbtA and OPS-TT [LVS O-polysaccharide (OPS) conjugated with–tetanus toxoid (TT)].
b
Vaccine route, dose: i.n., intranasal; i.d., intradermal.
c
Interval: Interval between the only or the last vaccination and challenge.
d
% Survival: % survival post-challenge in animals immunized with the vaccine candidate (vaccine), LVS control (LVS), or PBS or unvaccinated control (Sham); MST, Mean/Median Survival Time; ND, not determined.